DOCSLIB.ORG

ECIO 2021 Disclosures

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ECIO 2021 Disclosures Pres. No. Presenter Disclosure Company G. Argilés ​​Honoraria or consultation 101.2 Roche, Amgen, Merck Serono, BMS, Bayer, Sevier (New York, US) fees G. Argilés 101.2 Grants/​​research supports Bayer (New York, US) R. Duran ​​Honoraria or consultation 101.3 BTG/Boston Scientific, Guerbet (Lausanne, CH) fees R. Duran Society of Interventional Oncology/Immuno-oncology 101.3 Grants/​​research supports (Lausanne, CH) Research Grant, BTG/Boston Scientific, Guerbet F. Veloso Gomes ​​Honoraria or consultation 102.1 Bayer, Roche (Lisbon, PT) fees F. Veloso Gomes 102.1 Grants/​​research supports Terumo (Lisbon, PT) N. Costa Speaker agreement for Merit Medical, Terumo, Bayer 102.3 ​​Other support (Lisbon, PT) and Philips M. R. Meijerink ​​Honoraria or consultation 301.1 Medtronic, Angiodynamics (Amsterdam, NL) fees M. R. Meijerink Medtronic, Angiodynamics, Johnson-Johnson, Bristol- 301.1 Grants/​​research supports (Amsterdam, NL) Myers-Squibb J. Palussière 401.3 Grants/​​research supports Boston Scientific (Bordeaux, FR) C. Pettinato ​​Honoraria or consultation 401.4 Sirtex (Milan, IT) fees P. Schirmacher ​​Honoraria or consultation 402.1 Roche, BMS, Incyte, MSD (Heidelberg, DE) fees Participation in a company P. Schirmacher 402.1 sponsored speaker’s Janssen, Incyte (Heidelberg, DE) bureau​ P. Schirmacher 402.1 Grants/​​research supports BMS, Incyte (Heidelberg, DE) J. Debus 402.4 Grants/​​research supports Merck Serono, Siemens, Accuray (Heidelberg, DE) Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, A. Vogel ​​Honoraria or consultation 402.5 AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, (Hannover, DE) fees Janssen T. De Baère ​​Honoraria or consultation 402.6 Sirtex / Boston Scientific / Terumo (Villejuif, FR) fees T. De Baère 402.6 Grants/​​research supports Terumo (Villejuif, FR) J. H. Geschwind ​​Honoraria or consultation 501.3 Philips Healthcare (Northbrook, US) fees J. Chapiro 501.5 Grants/​​research supports SIO, Guerbet, Philips, Boston Scientific, NIH, RSNA (New Haven, US) M. Callstrom ​​Honoraria or consultation 502.3 Varian, Medtronic, Johnson and Johnson (Rochester, US) fees M. T. Reinders-Hut ​​Honoraria or consultation 701.3 Speaker for Boston Scientific (Utrecht, NL) fees Pres. No. Presenter Disclosure Company M. T. Reinders-Hut The Nuclear Medicine department of the University 701.3 ​​Other support (Utrecht, NL) Medical Center Utrecht receives royalties from Terumo M. T. Reinders-Hut I'm funded by a grant received by Prof. Lam from the 701.3 Grants/​​research supports (Utrecht, NL) Dutch Cancer Society (KWF Kankerbestrijding) H. J. Scheffer Adessium foundation, Angiodynamics, Stichting 702.1 Grants/​​research supports (Amsterdam, NL) nationaal fonds tegen kanker T. De Baère ​​Honoraria or consultation Terumo, Guerbet, General Electric Healthcare, Boston 801.1 (Villejuif, FR) fees Scientific T. De Baère 801.1 Grants/​​research supports Terumo, Boston Scientific (Villejuif, FR) F. Veloso Gomes ​​Honoraria or consultation 801.2 Bayer, Roche (Lisbon, PT) fees F. Veloso Gomes 801.2 Grants/​​research supports Terumo (Lisbon, PT) T. De Baère ​​Honoraria or consultation 901.1 Terumo, Guerbet, GE Healthcare, Boston Scientific (Villejuif, FR) fees R. Kloeckner ​​Honoraria or consultation Boston Scientific, Bristol-Myers Squibb, Guerbet, Sirtex, 901.2 (Mainz, DE) fees Roche Participation in a company R. Kloeckner BTG/Boston Scientific, EISAI, Guerbet, Ipsen, Roche, 901.2 sponsored speaker’s (Mainz, DE) Siemens, Sirtex, MSD - Merck Sharp & Dohme bureau​ R. Duran ​​Honoraria or consultation 901.3 BTG/Boston Scientific, Guerbet (Lausanne, CH) fees R. Duran Society of Interventional Oncology, BTG/Boston 901.3 Grants/​​research supports (Lausanne, CH) Scientific, Guerbet J. Ricke ​​Honoraria or consultation 1001.3 Sirtex, Boston Scientific, Terumo (Munich, DE) fees J. Ricke 1001.3 Grants/​​research supports Sirtex, Boston Scientific, Terumo (Munich, DE) T. De Baère ​​Honoraria or consultation 1001.4 Terumo / Guerbet (Villejuif, FR) fees T. De Baère 1001.4 Grants/​​research supports Terumo / Guerbet (Villejuif, FR) P. L. Pereira ​​Honoraria or consultation 1001.5 Terumo (Heilbronn, DE) fees E. De Kerviler ​​Honoraria or consultation 1002.1 Boston Scientific, Guerbet, Canon Medical (Paris, FR) fees J. L. Hinshaw ​​Honoraria or consultation 1002.3 Neuwave Medical (Madison, US) fees J. L. Hinshaw 1002.3 ​​​​Stock shareholder​ Accure Medical, Histosonics, Cellectar, Elucent (Madison, US) Achilles Tx, BioNTech, BMS, Eisai, Gadeta, Ipsen, J. Haanen ​​Honoraria or consultation Immunocore, MSD, Merck Serono, Molecular Partners, 1101.4 (Amsterdam, NL) fees Neogene Tx, Pfizer, Roche, Sanofi, Seattle Genetics, T-Knife, Third Rock Ventures Pres. No. Presenter Disclosure Company J. Haanen 1101.4 ​​​​Stock shareholder​ Neogene Tx (Amsterdam, NL) J. Haanen 1101.4 Grants/​​research supports Amgen, BMS, BioNTech, MSD, Novartis (Amsterdam, NL) D. Sze ​​Honoraria or consultation 1101.6 Replimune for DSMB (Stanford, US) fees T. Bryant ​​Honoraria or consultation 1102.2 Boston Scientific, Terumo, Celonova (Southampton, GB) fees Participation in a company T. Bryant 1102.2 sponsored speaker’s Guerbet, Boston Scientific (Southampton, GB) bureau​ T. Bryant 1102.2 Grants/​​research supports Coook Medical, BTG, Guerbet (Southampton, GB) T. De Baère ​​Honoraria or consultation 1201.2 Galil, Terumo, Medtronic (Villejuif, FR) fees J. Garnon ​​Honoraria or consultation 1201.3 Boston, J&J, Canon, Medtronic (Strasbourg, FR) fees C. Pettinato ​​Honoraria or consultation 1301.2 Sirtex (Milan, IT) fees J. K. Bell ​​Honoraria or consultation 1301.4 Boston/BTG, Roche, Sirtex, Terumo (Manchester, GB) fees E. Garin ​​Honoraria or consultation 1301.6 Boston (Rennes, FR) fees E. Garin 1301.6 Grants/​​research supports Boston (Rennes, FR) J. Jennings ​​Honoraria or consultation Stryker, Bard/BD, Varian, Boston Scientific, 1302.2 (Saint Louis, US) fees Teleflex/Arrow Merit Medical Systems, Cosmotec Fuji Pharma, Canon Medical Systems, Canon Medical Systems Asia Pte. Ltd. Canon Medical Systems Malaysia Sdn. Bhd., Sumitomo Y. Arai ​​Honoraria or consultation 1302.6 Bakelite, Boston Scientific Japan, Boston Scientific (Tokyo, JP) fees Corporation, Japan Lifeline, AstraZeneca plc Guerbet Japan, Guerbet Asia Pacific, Kyorin Pharmaceutical, Daiichi Sankyo Co., Ltd., Eisai Co., Ltd. H. Levillain ​​Honoraria or consultation 1401.1 Sirtex (Brussels, BE) fees Participation in a company H. Levillain 1401.1 sponsored speaker’s Sirtex (Brussels, BE) bureau​ I. Bargellini ​​Honoraria or consultation Sirtex, BTG Biocompatibles, Terumo, Bayer, Guerbet, 1401.2 (Pisa, IT) fees EISAI, Ge Healthcare I. Bargellini 1401.2 Grants/​​research supports BTG Biocompatibles (Pisa, IT) J. Ricke ​​Honoraria or consultation 1401.3 Sirtex, Boston Scientific, Terumo (Munich, DE) fees J. Ricke 1401.3 Grants/​​research supports Sirtex, Boston Scientific, Terumo (Munich, DE) Pres. No. Presenter Disclosure Company F. Cornelis 1501.1 ​​Other support compensated for presentation (Paris, FR) G. Mauri ​​Honoraria or consultation 1602.1 Elesta SrL (Milano, IT) fees M. R. Meijerink ​​Honoraria or consultation 1602.2 Angiodynamics, Medtronic (Amsterdam, NL) fees M. R. Meijerink Medtronic, Angiodynamics, Johnson-Johnson, Bristol- 1602.2 Grants/​​research supports (Amsterdam, NL) Myers-Squibb G. Gahide ​​Honoraria or consultation 1701.2 Boston Scientifics (Sherbrooke, CA) fees F. Lee ​​Honoraria or consultation 1701.5 Ethicon, Inc. (Madison, US) fees F. Lee 1701.5 ​​​​Stock shareholder​ Histosonics, Inc. (Madison, US) F. Lee 1701.5 ​​Other support Medtronic Inc (Inventions, patents royalties) (Madison, US) F. Lee 1701.5 Grants/​​research supports Histosonics, Inc. (Madison, US) T. Wah ​​Honoraria or consultation 1702.2 Angiodynamics (Leeds, GB) fees R. F. Grasso ​​Honoraria or consultation 1801.1 JJ consulting (Rome, IT) fees R. Suh ​​Honoraria or consultation Boston Scientific; Neuwave Medical; Boehringer 1801.2 (Los Angeles, US) fees Ingelheim; Ethicon D. Sheeran 2001.1 Grants/​​research supports Siemens Medical (Charlottesville, US) J. Angle 2001.2 Grants/​​research supports Siemens Medical (Charlottesville, US) J. Garnon ​​Honoraria or consultation 2101.2 Canon, J&J, Boston, Medtronic (Strasbourg, FR) fees E. Noll ​​Honoraria or consultation 2202.1 MSD, Edwards Life Science, Masimo (Strasbourg, FR) fees R. Cazzato ​​Honoraria or consultation 2202.3 Medtronic (Strasbourg, FR) fees J. Jennings ​​Honoraria or consultation Stryker, Bard/BD, Varian, Boston Scientific, 2202.4 (Saint Louis, US) fees Teleflex/Arrow S. Solomon ​​Honoraria or consultation Varian, Olympus, Advantagene, Aspire Bariatrics, 2301.5 (New York, US) fees Aperture Medical S. Solomon 2301.5 ​​​​Stock shareholder​ Johnson & Johnson, Aperture Medical, Aspire Bariatrics (New York, US) S. Solomon Johnson & Johnson (Neuwave), GE Healthcare, Elesta, 2301.5 Grants/​​research supports (New York, US) AngioDynamics R. Suh ​​Honoraria or consultation Boston Scientific; Neuwave Medical; Boehringer 2301.6 (Los Angeles, US) fees Ingelheim; Ethicon B. J. Wood 2302.3 ​​Other support see slide # 2- long list (Bethesda, US) B. J. Wood 2302.3 Grants/​​research supports See slide # 2- long list (Bethesda, US) Pres. No. Presenter Disclosure Company M. Bellini ​​Honoraria or consultation P-96 Stryker Italia (Siena, IT) fees J. P. Jones P-105 ​​Other support Employee (Salt Lake City, US) I. Paolucci Stefan Weber is co-founder and shareholder of P-133 ​​​​Stock shareholder​ (Bern, CH) CAScination I. Paolucci H2020-MSCA-ITN Project No. 722068 HiPerNav, Swiss P-133 Grants/​​research supports (Bern, CH) Cancer League, Professor Dr. Max Cloëtta Foundation.
Load more

Recommended publications
  • Biocompatibles Presentation 20091203
    Biocompatibles International plc Agenda • Overview • Key Programmes: Overview and Update: – Oncology Products: Drug-Eluting Beads – Oncology Products: Radiation Seeds – Licensing: Medtronic – Licensing: CellMed – AstraZeneca, Merz, Stroke • Financial Review and 2009 Goals Five Key Points for New Investors • Business Overview – Oncology Products : Proprietary Medical Devices: • Drug-Eluting Beads • Radiation Seeds – Licensing : Ambitious R&D/Partnering programmes: • AstraZeneca • Medtronic • Sales of £25m, growing at 30%+ per annum • Dividend of 5p/share paid in May 2009 • Contribution to R&D of £12m. Net R&D of £14m* • Net funds of £30m…market cap. of £95m** * Illustrative doubling of half-year figures ** Market cap. based on share price of 241.5p on 20 November, 2009 Two Divisions in Three Locations GROUP Oncology Products Licensing US and UK Mainly Germany Sales: £18m Sales: £7m Not Partnered Bead Brachytherapy AstraZeneca Products Products Medtronic Stroke Merz RNAi Group Sales £m 15 Mid Guidance 10 CellMed Licensing BrachySciences Beads 5 0 H1 2005 H2 2005 H1 2006 H2 2006 H1 2007 H2 2007 H1 2008 H2 2008 H1 2009 H2 2009 Sales Growth and Data are driving Value • 2009-11: • Dividend • Financial Guidance and Goals • Drug-Eluting Beads: • Continuing the growth • China and Japan • Accumulating clinical data • Acquisitions / Business Development • Towards break-even and profit • 2011-12 inflection points – AstraZeneca potential option exercise – Drug-Eluting Beads breakthrough: • SPACE • PARAGON Studies Agenda • Overview • Key Programmes:
    [Show full text]
  • Medical Research Council
    Elan Pharmaceuticals University of Kansas Parke-Davis Basilea Pharmaceutica Office of Rare Diseases (ORD) Swedish Orphan Biovitrum Astellas Pharma US, Inc. Food and Drug Administration (FDA) Biogen Idec AVEO Pharmaceuticals, Inc. Bioclin Research Laboratories Rare Diseases Clinical Research Network Birmingham Clinical Trials Unit Astellas Pharma Inc Baylor College of Medicine Astellas Pharma Europe BV Abbott Biotherapeutics Corp. OSI Pharmaceuticals Anglo-European College of Chiropractic The Beverage Institute. National Development and Research Institutes, Inc. Boston University University of Rochester Medstar Research Institute Omnicare Clinical Research ABX-CRO Bio-Kinetic Europe Ltd MRC Human Nutrition Research, Cambridge, UK. Shionogi Astellas Pharma Global Development, Inc. Ethicon, Inc. Symphogen A/S Averion-Hesperion Quintiles Laboratories Temple University Emory University National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) European Chiropractors Union Children's Hospital Boston Colchester Hospital University NHS Foundation Trust Covance GE Healthcare EMSI National Institute for Chiropractic Research Muscular Dystrophy Association Phoenix Children's Hospital OMRIX Biopharmaceuticals University of California, Los Angeles Cancer and Leukemia Group B University Health Network, Toronto University of Iowa Sarcoma Alliance for Research through Collaboration Westat Medivation, Inc. International Breast Cancer Study Group National Institute of Neurological Disorders and Stroke (NINDS) ClinPhone, Inc. Southwest Oncology Group Multi-Imagem and CDPI, Rio de Janeiro, Brasil Dutch Cancer Society Gary Cutter, PhD Murdoch Childrens Research Institute Chiltern International Inc. Janssen Research & Development, LLC Birmingham Children's Hospital NHS Foundation Trust Southwestern Oncology Group (SWOG) CIHR Canadian HIV Trials Network Royal Liverpool University Hospital Vertex Pharmaceuticals Incorporated UCB, Inc. Royal Hospital for Sick Children Trimeris Cystic Fibrosis Foundation Eisai Limited Eisai Inc.
    [Show full text]
  • Selective Internal Radiation Therapies For
    This is a repository copy of Selective internal radiation therapies for unresectable early-, intermediate or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/166248/ Version: Published Version Article: Walton, Matthew James orcid.org/0000-0003-1932-3689, Wade, Ros orcid.org/0000-0002- 8666-8110, Claxton, Lindsay orcid.org/0000-0002-1795-7568 et al. (6 more authors) (2020) Selective internal radiation therapies for unresectable early-, intermediate or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. Health Technology Asssessment. ISSN 2046-4924 https://doi.org/10.3310/hta24480 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Journals Library Health Technology Assessment Volume 24 •
    [Show full text]
  • Oncology Drugs in the Pipeline
    60 HemOnc today | MAY 25, 2013 | Healio.com/HemOnc Oncology Drugs in the Pipeline HemOnc Today presents the most recent information about oncology drugs in the pipeline. Drugs listed here are in phase 2 or phase 3 development for a variety of indications. Clinicians can use this chart as a quick reference to learn about the status of those drugs that may be clinically signifi cant to their practice. GGenericeneric nnameame ((BrandBrand nname,ame, MManufacturer)anufacturer) IIndication(s)ndication(s) DDevelopmentevelopment sstatustatus 131I-chTNT-1/B mAb (Cotara, Peregrine Pharmaceuticals) glioblastoma phase 2 18F-fl uorothymidine (Merck) breast cancer diagnosis phase 2 A6 (Angstrom Pharmaceuticals) ovarian cancer phase 2 abagovomab (Menarini) ovarian cancer phase 3 abexinostat (Pharmacyclics) follicular lymphoma, mantle cell lymphoma phase 2 ABI-008 (Celgene) prostate cancer phase 2 ABIO-0501 (Abiogen Pharma) chronic myeloid leukemia phase 2 abiraterone (Zytiga, Janssen Biotech) breast cancer/prostate cancer phase 2/phase 3 ABT-888 (Abbott Laboratories) breast cancer, colorectal cancer, fallopian tube cancer, lymphoma, mela- phase 2 noma, non–small cell lung cancer, ovarian cancer ACE-041 (Acceleron Pharma) head and neck cancers phase 2 acolbifene (EndoCeutics) breast cancer phase 2 ACY-1215 (Acetylon Pharmaceuticals) myeloma phase 2 ado-trastuzumab emtansine (Kadcyla, Genentech) fi rst-line and third-line HER-2–positive breast cancer phase 3 ADXS-HPV(Advaxis) cervical cancer phase 2 AE37 peptide vaccine (Antigen Express) breast cancer phase 2 AEE788 (Novartis Pharmaceuticals) glioblastoma phase 2 AEG35156 (Aegera Therapeutics) acute myelogenous leukemia, chronic lymphocytic leukemia, B-cell phase 2 lymphoma AEZS-108 (Aeterna Zentaris) bladder cancer, endometrial cancer, ovarian cancer, prostate cancer phase 2 afatinib (Boehringer Ingelheim) glioblastoma/breast cancer, non–small cell lung cancer, head and neck phase 2/phase 3 READ PERSPECTIVE cancers on this drug from Tobenna Nwizu, MD, on page 76.
    [Show full text]
  • Representing the Drug Or Medical Device Manufacturer in an Investigation
    This material is chapter 10 of Deskbook on Internal Investigations, Corporate Compliance, and White Collar Issues (2nd ed.), by Arnold & Porter Kaye Scholer LLP (©2016 & Supp. 2019 by Practising Law Institute), www.pli.edu. Reprinted with permission for www.arnoldporter.com. Not for resale or redistribution. Chapter 10 Representing the Drug or Medical Device Manufacturer in an Investigation § 10:1 Introduction § 10:2 The Statutory and Regulatory Scheme § 10:2.1 The FDCA § 10:2.2 The Anti-Kickback Statute § 10:2.3 The False Claims Act § 10:2.4 The Foreign Corrupt Practices Act § 10:2.5 Other Regulatory Tools [A] Corporate Integrity Agreements [B] Exclusion from Federal Healthcare Programs [C] Fines § 10:3 Recent Developments in Enforcement Actions § 10:3.1 Enforcement Actions Against Pharmaceutical Manufacturers § 10:3.2 Enforcement Actions Against Medical Device Manufacturers § 10:3.3 Individual Accountability § 10:3.4 Sorrell, Caronia, and First Amendment Challenges § 10:4 FDA Warning and Untitled Letters to Pharmaceutical Companies Regarding Promotional Materials § 10:5 Compliance Strategies § 10:6 Conclusion (White Collar, Rel. #6, 11/19) 10–1 ©2016 & Supp. 2019 by Practising Law Institute. § 10:1 White Collar Issues Deskbook § 10:1 Introduction The variety of criminal statutes and theories used to prosecute drug and device manufacturers is so diverse as to defy easy summary. At one end of the spectrum are those dealing with general offenses, such as the Civil War–era statute criminalizing the submission of false claims to a department or agency of the United States,1 or the mail2 and wire fraud3 statutes—each of which could be used by the government against pharmaceutical companies and medical device manufacturers and their executives.
    [Show full text]
  • Venous Thromboembolism in Over 16S: Reducing the Risk of Hospital-Acquired Deep Vein Thrombosis Or Pulmonary Embolism (Update) Stakeholders
    Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (Update) Stakeholders Academy for Healthcare Science Active Lifestyles, Salford Community Leisure Alere Ltd AntiCoagulation Europe ArjoHuntleigh Ashford and St Peter's Hospitals NHS Trust Association for Perioperative Practice Association of Anaesthetists of Great Britain and Ireland Association of Directors of Public Health Association of Independent Healthcare Organisations Astrazeneca UK Ltd Atrial Fibrillation Association Australian Commission on Safety and Quality in Health Care Barnet Enfield and Haringey Mental Health Trust Barnsley Hospital NHS Foundation Trust Barts Health NHS Trust Basildon and Thurrock University Hospitals NHS Foundation Trust Bayer plc Belfast Health and Social Care Trust Besins Healthcare Betsi Cadwaladr University Health Board BHR Pharmaceuticals Ltd Biocompatibles Birmingham Women’s NHS Foundation Trust Black and Ethnic Minority Diabetes Association Boehringer Ingelheim Ltd Bolton Council Boston Scientific Bristol-Myers Squibb Pharmaceuticals Ltd British Association of Critical Care Nurses British Association of Day Surgery British Association of Prosthetists & Orthotists British Dietetic Association British Geriatrics Society British Heart Foundation British Lymphology Society British Medical Association British Medical Journal British National Formulary British Nuclear Cardiology Society British Orthopaedic Association British Pregnancy Advisory Service British Psychological Society British
    [Show full text]
  • Royal Free London NHS Foundation Trust Open Studies
    Royal Free London NHS Foundation Trust Open Studies R&D No Short Title Sponsor Organisation Principal Investigator EuroSIDA HIV/AIDS 10 year Eurpean cohort - European Virology co-ordinating 5162 Centre for Health and Infectious Disease Research Professor Clive Loveday centre (2000-2004) 5658 Fabry outcome survey [FOS] Shire Human Genetic Therapies UK Ltd Dr Derralynn Hughes 6339 Clinical pancreatic islet transplantation in patients with insulin dependent diabetes. The Royal Free Hospital Dr Martin Press Elucidating the pathogenesis of systemic sclerosis by studying skin, blood and 6398 Royal Free London NHS Foundation Trust Prof Carol M Black tissue samples from s Non-invasive prenatal diagnosis of haemophilia using free fetal DNA in maternal 6441 Royal Free London NHS Foundation Trust Miss Rezan A Abdul-Kadir plasma. British Regional Heart Study (BRHS). Strategies for the prevention of cardiovascular 6755 University College London Professor P Whincup disease in olde Database of patients with movement disorders and prospective collection and 6540 UCL Dr Anette Schrag storage of DNA samples. 6884 The Investigation of the cause and the mechanism of Immunodeficiency diseases. Royal Free London NHS Foundation Trust Prof Bodo Grimbacher Bilibaby- The Relationship Between Neonatal Scleral Tone and Serum Bilirubin 6899 UCL Dr Alastair. Sutcliffe Levels. 7190M Identification and molecular analyses of families with susceptibility to breast cancer. ICR Dr James Mackay The Gaucher Registry: an ongoing, observational database that tracks the natural
    [Show full text]